JP2022507534A5 - - Google Patents

Info

Publication number
JP2022507534A5
JP2022507534A5 JP2021526562A JP2021526562A JP2022507534A5 JP 2022507534 A5 JP2022507534 A5 JP 2022507534A5 JP 2021526562 A JP2021526562 A JP 2021526562A JP 2021526562 A JP2021526562 A JP 2021526562A JP 2022507534 A5 JP2022507534 A5 JP 2022507534A5
Authority
JP
Japan
Application number
JP2021526562A
Other languages
Japanese (ja)
Other versions
JPWO2020102723A5 (https=
JP7532360B2 (ja
JP2022507534A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061808 external-priority patent/WO2020102723A1/en
Publication of JP2022507534A publication Critical patent/JP2022507534A/ja
Publication of JPWO2020102723A5 publication Critical patent/JPWO2020102723A5/ja
Publication of JP2022507534A5 publication Critical patent/JP2022507534A5/ja
Application granted granted Critical
Publication of JP7532360B2 publication Critical patent/JP7532360B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526562A 2018-11-16 2019-11-15 ウィルソン病を処置するための組成物および方法 Active JP7532360B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862768744P 2018-11-16 2018-11-16
US62/768,744 2018-11-16
PCT/US2019/061808 WO2020102723A1 (en) 2018-11-16 2019-11-15 Compositions and methods for treating wilson's disease

Publications (4)

Publication Number Publication Date
JP2022507534A JP2022507534A (ja) 2022-01-18
JPWO2020102723A5 JPWO2020102723A5 (https=) 2023-06-27
JP2022507534A5 true JP2022507534A5 (https=) 2023-06-27
JP7532360B2 JP7532360B2 (ja) 2024-08-13

Family

ID=70731690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526562A Active JP7532360B2 (ja) 2018-11-16 2019-11-15 ウィルソン病を処置するための組成物および方法

Country Status (7)

Country Link
US (1) US20210369870A1 (https=)
EP (2) EP4257155A3 (https=)
JP (1) JP7532360B2 (https=)
CN (1) CN113302290A (https=)
CA (1) CA3118936A1 (https=)
TW (1) TW202039854A (https=)
WO (1) WO2020102723A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019007873A (es) 2016-12-30 2019-11-18 Univ Pennsylvania Terapia génica para tratar la enfermedad de wilson.
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
KR20210112339A (ko) 2019-01-04 2021-09-14 울트라제닉스 파마수티컬 인코포레이티드 윌슨병을 치료하기 위한 유전자 요법 구축물
WO2022208342A1 (en) * 2021-04-01 2022-10-06 Pfizer Inc. Pharmaceutical compositions containing adeno-associated viral vector
CN115216481A (zh) * 2021-04-21 2022-10-21 四川至善唯新生物科技有限公司 一种表达量提高的截短型atp7b基因及其应用
CN113699211A (zh) * 2021-07-20 2021-11-26 深圳市儿童医院 一种用于儿童威尔森氏症快速筛查的参数组合和试剂盒
EP4398896A4 (en) * 2021-09-07 2025-07-02 Alexion Pharma Inc METHODS FOR TREATING DISEASES OR DISORDERS ASSOCIATED WITH COPPER METABOLISM
US20250144239A1 (en) * 2021-10-18 2025-05-08 Logicbio Therapeutics, Inc. Gene therapy for the treatment of wilson's disease
KR20250102134A (ko) * 2022-10-11 2025-07-04 메이라지티엑스 유케이 Ii 리미티드 Atp7b 유전자 요법
WO2024183769A1 (en) * 2023-03-06 2024-09-12 Lingyi Biotech Co., Ltd. A truncated atp7b and the use thereof
JP2026508707A (ja) * 2023-03-22 2026-03-11 スカイライン、セラピューティクス、リミテッド ウィルソン病の遺伝子療法のための組換えaav
WO2025002226A1 (zh) * 2023-06-28 2025-01-02 迈威(上海)生物科技股份有限公司 编码atp7b的核酸、腺相关病毒载体及其在制备防治肝豆状核变性的药物中的应用
WO2025026198A1 (en) * 2023-07-28 2025-02-06 Lingyi Biotech Co., Ltd. Polynucleotides for the treatment of wilson disease
CN117757797B (zh) * 2023-09-25 2024-08-16 北京圭特细胞科技有限公司 一种编码人III型胶原蛋白α链的核酸及其应用
WO2025110984A1 (en) * 2023-11-21 2025-05-30 Hydrogene Therapeutics, Inc. Compositions and methods for treating wilson's disease
CN117947035A (zh) * 2024-03-25 2024-04-30 上海凌医生物科技有限公司 一种增强基因表达的启动子
CN121265551A (zh) * 2024-07-02 2026-01-06 苏州星核迪赛生物技术有限公司 一种靶向肝实质细胞的核酸递送载体及其应用
CN121319202B (zh) * 2025-12-15 2026-04-07 凌意(杭州)生物科技有限公司 Atp7b抗体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
ES2284545T3 (es) * 1999-11-16 2007-11-16 Genzyme Corporation Vectores y transgenes con elementos reguladores para la administracion de genes del higado.
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
DE602004030327D1 (de) 2003-05-21 2011-01-13 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
EP1660970A4 (en) 2003-08-01 2007-02-14 Dna Twopointo Inc SYSTEMS AND METHODS FOR BIOPOLYMER TECHNOLOGY
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
BRPI0619794B8 (pt) 2005-12-13 2022-06-14 Univ Kyoto Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
HUE028341T2 (en) 2009-06-16 2016-12-28 Genzyme Corp Improved methods for purification of recombinant aav vectors
US20150045284A1 (en) 2011-01-21 2015-02-12 Aarhus Universitet CRYSTAL STRUCTURE OF A TYPE IB P-TYPE ATPase
WO2015121793A1 (en) * 2014-02-11 2015-08-20 Friedrich Miescher Institute For Biomedical Research Müller cell-specific promoter
ES2876412T3 (es) * 2014-12-17 2021-11-12 Fundacion Para La Investig Medica Aplicada Construcciones de ácido nucleico y vectores de terapia génica para su uso en el tratamiento de la enfermedad de Wilson
EP3233129B1 (en) 2014-12-17 2020-01-15 Fundacion para la Investigacion Medica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions
KR102580696B1 (ko) * 2014-12-30 2023-09-19 큐어백 에스이 신규 인공 핵산 분자
EP3270944B1 (en) 2015-03-17 2019-10-23 Vrije Universiteit Brussel Optimized liver-specific expression systems for fviii and fix
GB201522416D0 (en) 2015-12-18 2016-02-03 Ucl Business Plc Wilson's disease gene therapy
MX2019007873A (es) 2016-12-30 2019-11-18 Univ Pennsylvania Terapia génica para tratar la enfermedad de wilson.
WO2018204764A1 (en) * 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021018450A2 (https=)
JP2022507534A5 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021017083A2 (https=)
BR112021012348A2 (https=)
BR112021018250A2 (https=)